Cover Image
市場調查報告書

鼻咽癌:開發中產品分析

Nasopharyngeal Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229772
出版日期 內容資訊 英文 258 Pages
訂單完成後即時交付
價格
Back to Top
鼻咽癌:開發中產品分析 Nasopharyngeal Cancer - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 258 Pages
簡介

鼻咽癌是發生於頸部及頭部的罕見型癌症,常發生在喉嚨上部或鼻子內側。這部分被稱為鼻咽頭,鼻咽癌的危險因子是EB病毒。症狀有視線模糊或複視、包含嘶啞的發聲困難、不斷重複的耳道感染、臉部疼痛或是無知覺、頭痛、重聽、耳鳴等。治療方法有手術、化療及放射線療法等。

本報告提供鼻咽癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

鼻咽癌 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Advenchen Laboratories, LLC
  • Ambrx, Inc.
  • arGEN-X BV
  • Atara Biotherapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Betta Pharmaceuticals Co. Ltd.
  • BioDiem Ltd
  • Biomics Biotechnologies Co., Ltd.
  • Celgene Corporation
  • Cell Medica Limited
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lakewood-Amedex Inc
  • Merck & Co., Inc.
  • Merck KGaA
  • Molecular Partners AG
  • Novartis AG
  • 小野藥品工業
  • Pharmacyclics, Inc.
  • Sapvax
  • Tessa Therapeutics Pte Ltd
  • Theravectys SA

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9100IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 12, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 7, 2 and 6 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasopharyngeal Cancer - Overview
    • Nasopharyngeal Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nasopharyngeal Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nasopharyngeal Cancer - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • Ambrx Inc
    • arGEN-X BV
    • Ascentage Pharma Group Corp Ltd
    • Atara Biotherapeutics Inc
    • AVEO Pharmaceuticals Inc
    • BeiGene Ltd
    • Betta Pharmaceuticals Co Ltd
    • BioDiem Ltd
    • Biomics Biotechnologies Co Ltd
    • CBT Pharmaceuticals Inc
    • Celgene Corp
    • Cell Medica Ltd
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • MedImmune LLC
    • Merck & Co Inc
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Neonc Technologies Inc
    • Novartis AG
    • Ono Pharmaceutical Co Ltd
    • Sapvax
    • Tessa Therapeutics Pte Ltd
    • Theravectys SA
    • Viracta Therapeutics Inc
    • Yabao Pharmaceutical Group Co Ltd
  • Nasopharyngeal Cancer - Drug Profiles
    • alisertib - Drug Profile
    • Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile
    • apatinib - Drug Profile
    • APG-1387 - Drug Profile
    • ARGX-110 - Drug Profile
    • ATA-129 - Drug Profile
    • atezolizumab - Drug Profile
    • avelumab - Drug Profile
    • azacitidine - Drug Profile
    • baltaleucel-T - Drug Profile
    • bevacizumab - Drug Profile
    • BGBA-317 - Drug Profile
    • CBT-501 - Drug Profile
    • Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile
    • Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer - Drug Profile
    • Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Carcinoma - Drug Profile
    • Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile
    • Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile
    • DC-120 - Drug Profile
    • donafenib - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • EBViNT - Drug Profile
    • Epstein-Barr virus vaccine - Drug Profile
    • ficlatuzumab - Drug Profile
    • GSK-2849330 - Drug Profile
    • icotinib hydrochloride - Drug Profile
    • JS-001 - Drug Profile
    • MAK-683 - Drug Profile
    • Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile
    • Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
    • MVA vaccine - Drug Profile
    • NEO-212 - Drug Profile
    • nimotuzumab - Drug Profile
    • nivolumab - Drug Profile
    • PDR-001 - Drug Profile
    • pembrolizumab - Drug Profile
    • RO-5203280 - Drug Profile
    • Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer - Drug Profile
    • SV-638 - Drug Profile
    • TT-10 - Drug Profile
    • Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
    • Vaccine for Oncology - Drug Profile
    • Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
    • Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma - Drug Profile
    • VRx-3996 - Drug Profile
  • Nasopharyngeal Cancer - Dormant Projects
  • Nasopharyngeal Cancer - Discontinued Products
  • Nasopharyngeal Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Nasopharyngeal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Celgene Corp, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Merck KGaA, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Novartis AG, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Sapvax, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Theravectys SA, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H1 2017
  • Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H1 2017
  • Nasopharyngeal Cancer - Dormant Projects, H1 2017
  • Nasopharyngeal Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Nasopharyngeal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top